[go: up one dir, main page]

PE20070548A1 - Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico - Google Patents

Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico

Info

Publication number
PE20070548A1
PE20070548A1 PE2006001133A PE2006001133A PE20070548A1 PE 20070548 A1 PE20070548 A1 PE 20070548A1 PE 2006001133 A PE2006001133 A PE 2006001133A PE 2006001133 A PE2006001133 A PE 2006001133A PE 20070548 A1 PE20070548 A1 PE 20070548A1
Authority
PE
Peru
Prior art keywords
sodium salt
cnac
chlorosaliciloyl
amino acid
crystalline forms
Prior art date
Application number
PE2006001133A
Other languages
English (en)
Inventor
Nikhil Dhoot
Steven Dinh
Shingai Majuru
William Elliot Bay
Joanne P Corvino
Doris C O'toole
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of PE20070548A1 publication Critical patent/PE20070548A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA FORMA CRISTALINA I, II, III Y IV DE LA SAL DI-SODIO DEL ACIDO N-(5-CLOROSALICILOIL)-8-AMINOCAPRILICO (5-CNAC). EL MONOHIDRATO CRISTALINO DE LA SAL DI-SODIO DE 5-CNAC (FORMA I) PRESENTA UN PATRON DE DIFRACCION DE POLVO DE RAYO X (GRADOS 2 THETA) CARACTERISTICO CON PICOS DE 7.5, 10.4, 14.2, 15.0, 15.5, 16.1, ENTRE OTROS; EL SOLVATO DE ETANOL DE LA SAL DE 5-CNAC (FORMA II) PRESENTA PICOS SELECCIONADOS DE 7.5, 14.1, 16.5, 18.5, 25 Y 26; EL OCTAHIDRATO DE LA SAL DE 5-CNAC (FORMA III) PRESENTA PICOS SELECCIONADOS DE 4.8, 10.4, 11.7 Y 14.6; Y EL MONOHIDRATO CRISTALINO DE LA SAL DE DI-SODIO DE 5-CNAC (FORMA IV) PRESENTA PICOS SELECCIONADOS DE 7.2, 18.2 Y 24.7. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION.
PE2006001133A 2005-09-19 2006-09-18 Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico PE20070548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71882905P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
PE20070548A1 true PE20070548A1 (es) 2007-07-12

Family

ID=37889458

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010000134A PE20100241A1 (es) 2005-09-19 2006-09-18 Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
PE2006001133A PE20070548A1 (es) 2005-09-19 2006-09-18 Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2010000134A PE20100241A1 (es) 2005-09-19 2006-09-18 Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico

Country Status (19)

Country Link
US (3) US8026392B2 (es)
EP (1) EP1937627A4 (es)
JP (1) JP2009508875A (es)
KR (1) KR20080049128A (es)
CN (2) CN105641686A (es)
AR (1) AR058053A1 (es)
AU (1) AU2006292337B8 (es)
BR (1) BRPI0616558B1 (es)
CA (1) CA2619673C (es)
GT (1) GT200600421A (es)
IL (1) IL189015A (es)
JO (1) JO3684B1 (es)
NZ (1) NZ566397A (es)
PE (2) PE20100241A1 (es)
RU (1) RU2507196C2 (es)
SG (1) SG165397A1 (es)
TW (1) TWI386386B (es)
WO (1) WO2007035718A2 (es)
ZA (1) ZA200803206B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101557827A (zh) * 2006-08-31 2009-10-14 诺瓦提斯公司 用于口服递送的包含hgh的药物组合物
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
ES3030918T3 (en) * 2020-05-29 2025-07-02 Sciwind Biosciences Co Ltd N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
WO2022226217A1 (en) * 2021-04-22 2022-10-27 Civi Biopharma, Inc. Oral delivery of oligonucleotides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
US5069419A (en) 1989-06-23 1991-12-03 Ic Sensors Inc. Semiconductor microactuator
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH11140064A (ja) * 1997-11-10 1999-05-25 Nippon Nohyaku Co Ltd １，２，３−チアジアゾール誘導体の製造方法及び中間体化合物
US6126140A (en) 1997-12-29 2000-10-03 Honeywell International Inc. Monolithic bi-directional microvalve with enclosed drive electric field
AU3378100A (en) * 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU4216700A (en) * 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
SK287697B6 (sk) 2001-06-01 2011-06-06 Novartis Ag Orálne podanie paratyroidného hormónu a kalcitonínu
SI1420827T1 (sl) 2001-08-17 2010-01-29 Novartis Ag 5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
CN1809377B (zh) * 2003-07-11 2010-08-04 诺瓦提斯公司 包含微粉化形式的传送剂的口服给药药物组合物
EP2316473B1 (en) * 2003-07-23 2013-08-21 Novartis AG Use of calcitonin in osteoarthritis
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2005286727A1 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
SG152229A1 (en) 2005-08-25 2009-05-29 Univ Arizona Stem cell fusion model of carcinogenesis
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation

Also Published As

Publication number Publication date
US20130303444A1 (en) 2013-11-14
WO2007035718A2 (en) 2007-03-29
CN105641686A (zh) 2016-06-08
IL189015A0 (en) 2008-08-07
TWI386386B (zh) 2013-02-21
CN101627011A (zh) 2010-01-13
KR20080049128A (ko) 2008-06-03
RU2507196C2 (ru) 2014-02-20
GT200600421A (es) 2012-03-16
TW200744993A (en) 2007-12-16
JP2009508875A (ja) 2009-03-05
IL189015A (en) 2016-09-29
US20080269108A1 (en) 2008-10-30
CA2619673A1 (en) 2007-03-29
EP1937627A4 (en) 2010-09-01
US9238074B2 (en) 2016-01-19
AU2006292337A1 (en) 2007-03-29
AR058053A1 (es) 2008-01-23
CA2619673C (en) 2018-07-10
JO3684B1 (ar) 2020-08-27
AU2006292337B8 (en) 2013-02-07
BRPI0616558B1 (pt) 2021-09-08
RU2008103699A (ru) 2009-10-27
US8431736B2 (en) 2013-04-30
EP1937627A2 (en) 2008-07-02
ZA200803206B (en) 2009-08-26
US8026392B2 (en) 2011-09-27
PE20100241A1 (es) 2010-04-16
WO2007035718A3 (en) 2009-06-18
NZ566397A (en) 2010-04-30
US20120065128A1 (en) 2012-03-15
BRPI0616558A2 (pt) 2011-06-21
SG165397A1 (en) 2010-10-28
AU2006292337B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AR059349A1 (es) Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona
CR6938A (es) Monohidrato cristalino metodo para su fabricacion y su empleo en la fabricacion de un medicamento.
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
HRP20100038T1 (hr) Farmaceutski vaginalni gel koji sadrži tenofovir
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
IL184771A (en) Preparations containing amino acids are stored in halogen or in the nitrogen for use.
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
BRPI0510231A (pt) composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
RU2009133262A (ru) Нападизилатная соль антагониста мускаринового мз-рецептора
PE20081157A1 (es) Forma cristalina de hemifumarato de alisquireno
PE20070548A1 (es) Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
ATE319729T1 (de) 9a-azalide mit entzündungshemmender wirkung
SG162744A1 (en) Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
AR075340A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a,formas cristalinas 1, 2 y 3, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento de enfermedades inflamatorias
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
RU2002107079A (ru) Вещество, обладающее седативным действием
PE20130377A1 (es) Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
AR056082A1 (es) Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
AR062204A1 (es) Formas solidas de (3'-clorobifeni-4-il)(1-pirimidin-2-il)piperidin-4-il)metanona, un metodo de preparacion, una dosificacion farmaceutica que la comprende y su uso en eltratamiento de trastornos cognitivos y de la enfermedad de alzheimer.
AR037636A1 (es) Clorhidrato de venlafaxina monohidrato y metodos para su preparacion
JP2004523567A5 (es)

Legal Events

Date Code Title Description
FC Refusal